TREATMENT OF HEPATITIS E VIRUS INFECTION WITH INTERFERON LAMBDA
Provided herein are methods of treating a hepatitis E virus (HEV) infection in a human patient are provided. The methods comprise administering to the patient a therapeutically effective amount of interferon lambda.
1 . A method of treating a hepatitis E virus (HEV) infection in a human patient, the method comprising administering the patient a therapeutically effective amount of interferon lambda.
2 . The method of claim 1 , wherein the interferon lambda is pegylated.
3 . The method of claim 2 , wherein the interferon lambda is pegylated interferon lambda-1a.
4 . The method of any one of claims 1 - 3 , wherein the interferon lambda is administered at a dose from 10 μg/kg to 500 μg/kg.
5 . The method of claim 4 , wherein the interferon lambda is administered at a dose from 10 μg/kg to 50 μg/kg.
6 . The method of claim 4 , wherein the interferon lambda is administered at a dose from 100 μg/kg to 500 μg/kg.
7 . The method of claim 4 , wherein the interferon lambda is administered at a dose from 100 μg/kg to 350 μg/kg or 250 μg/kg to 350 μg/kg or 275 μg/kg to 325 μg/kg.
8 . The method of claim 4 , wherein the interferon lambda is administered at a dose of 30 μg/kg.
9 . The method of any one of claims 1 - 3 , wherein the interferon lambda is administered twice weekly.
10 . The method of any one of claims 1 - 3 , wherein the interferon lambda is subcutaneously or intraperitoneally administered.
11 . The method of claim 10 , wherein the interferon lambda is subcutaneously administered.
12 . The method of any one of claims 1 - 3 , wherein the interferon lambda is administered for at least 4 weeks.
13 . The method of claim 12 , wherein the interferon lambda is administered for 8 weeks.
14 . The method of any one of claims 1 - 3 , wherein the treatment results in an HEV viral load that is below 100 IU/g tissue.
15 . The method of any one of claims 1 - 3 , wherein the treatment results in an HEV viral load that is below the level of detection.
16 . The method of any one of claims 1 - 3 , wherein the treatment results in an at least 3 log reduction in HEV viral load.
17 . The method of any one of claims 1 - 3 , further comprising administering an antiviral nucleotide or nucleoside analog.
18 . The method of claim 17 , wherein the antiviral nucleotide or nucleoside analog is administered at a dose from 10 mg/kg to 50 mg/kg.
19 . The method of claim 17 or 18 , wherein the antiviral nucleotide or nucleoside analog is administered at a daily dose from 29 mg to 1000 mg.
20 . The method of any of claims 17 - 19 , wherein the antiviral nucleotide or nucleoside analog is ribavirin.
21 . The method of any of claim 17 - 20 , wherein the antiviral nucleotide or nucleoside analog is ribavirin, and wherein the ribavirin is administered at a dose of 25 mg/kg.